Importantly, silencing transgene expression reversed the cardiac conduction abnormalities and myotonia, thus providing the first in vivo proof of principle for therapeutic strategies aimed at treating DM1 by silencing expression of, or getting rid of, the mutant DMPK mRNA [66]. The gene discussed is DMPK; the disease is myotonic dystrophy type 1.